Amgen Inc yesterday launched a Taiwanese affiliate to oversee the marketing of three new drugs that the US-based biotechnology giant has reacquired from GlaxoSmithKline PLC.
The company in December last year reacquired rights to three of its medicines from GlaxoSmithKline in 48 markets and the new affiliate, Amgen Taiwan (台灣安進藥品), has submitted marketing authorization transfer applications to the Food and Drug Administration.
The three drugs are comprised of two types of denosumab injections, Prolia and Xgeva, and Vectibix, an monoclonal antibody injection.
“At the time, the arrangement with GlaxoSmithKline made sense for both parties. However, once Amgen has established a foothold in Asia, the company is aiming to increase its global presence significantly,” Amgen Asia regional corporate communications director Mary Klem said.
Klem said that in addition to marketing, Amgen Taiwan is among the company’s five fully-fledged affiliates in Asia.
Amgen Taiwan’s priorities are to continue investing in clinical trials and promote its parent company’s products in the local market, bringing additional treatments for cardiovascular diseases, as well as oncology and biosimilar medicines, to the local market, Klem said.
GlaxoSmithKline held selected regional rights to the three products since 2010 and generated approximately US$111 million in combined sales from those licenses in 2014, Amgen data showed.
In the five-year period leading up to the launch of its Taiwanese affiliate, Amgen has invested about NT$120 million (US$3.68 million) in clinical trials in Taiwan, Amgen Taiwan general manager Kelvin Chen (陳光冠) said.
Although Chen did not rule out the possibility of local contractors manufacturing Amgen’s products, he said that option is not likely as the US-based company has ample capacity overseas.
“Several studies have taken place in Taiwan and more than 10 studies are ongoing, with more than 200 patients enrolled in clinical trials,” Chen said.
Amgen Taiwan has about 50 employees, Chen said.
Amgen Taiwan has also retained Lin Fu-kuen (林福坤) as a consultant. Lin played an instrumental role in isolating and then cloning erythropoietin, the principal hormone regulating red blood cell production.
Lin’s discoveries led to the commercialization of Amgen’s Epogen, which is used to treat a lower than normal number of red blood cells caused by chronic kidney disease in patients on dialysis.
Prolia is a treatment for osteoporosis for postmenopausal women at a high risk of bone fractures who are intolerant of other forms of osteoporosis therapy.
Xgeva prevents skeletal-related events in patients with bone metastases from solid tumors, such as radiation of the bones, pathologic fractures and spinal cord compression.
Vectibix is used in combination with chemotherapy as a first-line treatment of metastatic colorectal cancer.
Taiwan Transport and Storage Corp (TTS, 台灣通運倉儲) yesterday unveiled its first electric tractor unit — manufactured by Volvo Trucks — in a ceremony in Taipei, and said the unit would soon be used to transport cement produced by Taiwan Cement Corp (TCC, 台灣水泥). Both TTS and TCC belong to TCC International Holdings Ltd (台泥國際集團). With the electric tractor unit, the Taipei-based cement firm would become the first in Taiwan to use electric vehicles to transport construction materials. TTS chairman Koo Kung-yi (辜公怡), Volvo Trucks vice president of sales and marketing Johan Selven, TCC president Roman Cheng (程耀輝) and Taikoo Motors Group
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
RECORD-BREAKING: TSMC’s net profit last quarter beat market expectations by expanding 8.9% and it was the best first-quarter profit in the chipmaker’s history Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), which counts Nvidia Corp as a key customer, yesterday said that artificial intelligence (AI) server chip revenue is set to more than double this year from last year amid rising demand. The chipmaker expects the growth momentum to continue in the next five years with an annual compound growth rate of 50 percent, TSMC chief executive officer C.C. Wei (魏哲家) told investors yesterday. By 2028, AI chips’ contribution to revenue would climb to about 20 percent from a percentage in the low teens, Wei said. “Almost all the AI innovators are working with TSMC to address the
FUTURE PLANS: Although the electric vehicle market is getting more competitive, Hon Hai would stick to its goal of seizing a 5 percent share globally, Young Liu said Hon Hai Precision Industry Co (鴻海精密), a major iPhone assembler and supplier of artificial intelligence (AI) servers powered by Nvidia Corp’s chips, yesterday said it has introduced a rotating chief executive structure as part of the company’s efforts to cultivate future leaders and to enhance corporate governance. The 50-year-old contract electronics maker reported sizable revenue of NT$6.16 trillion (US$189.67 billion) last year. Hon Hai, also known as Foxconn Technology Group (富士康科技集團), has been under the control of one man almost since its inception. A rotating CEO system is a rarity among Taiwanese businesses. Hon Hai has given leaders of the company’s six